Bruceantin  (Synonyms: (-)-Bruceantin; NCI165563; NSC165563)

Bruceantin(NSC165563) is first isolated from Brucea javanica, a tree used in Ethiopia for the treatment of cancer, and activity was observed against B16 melanoma, colon 38, and L1210 and P388 leukemia in mice. IC50 value: Target: anticancer Cell differentiation was induced and c-MYC was down-regulated, suggesting a mechanistic correlation between c-MYC down-regulation and induction of cell differentiation or cell death. Treatment of HL-60 and RPMI 8226 cell lines induced apoptosis, and this involved the caspase and mitochondrial pathways. Moreover, an in vivo study using RPMI 8226 human-SCID xenografts demonstrated that bruceantin induced regression in early as well as advanced tumors, and these significant antitumor responses were facilitated in the absence of overt toxicity.

548.58

Solid

C₂₈H₃₆O₁₁

41451-75-6

O=C([[email protected]@]1([[email protected]]([[email protected]](O)[[email protected]]2([H])[[email protected]]3(C4)C)O)[[email protected]@]([[email protected]](C5=O)OC(/C=C(C)/C(C)C)=O)([H])[[email protected]@]2([[email protected]@](O5)([H])C[[email protected]@]3([H])C(C)=C(O)C4=O)CO1)OC

Room temperature in continental US; may vary elsewhere.

• [1]. Cuendet M, et al. Multiple myeloma regression mediated by bruceantin. Clin Cancer Res. 2004 Feb 1;10(3):1170-9.  [Content Brief]

  [2]. Cuendet M, et al. Antitumor activity of bruceantin: an old drug with new promise. J Nat Prod. 2004 Feb;67(2):269-72.  [Content Brief]